OGN - Organon - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68622V1061
Contraceptives, Fertility medicines, Biosimilars, Oncology products, Cholesterol medicines
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey. Web URL: https://www.organon.com
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for OGN - Organon - Stock Price & Dividends](https://www.valueray.com/images/drawdown_chart/OGN.NYSE_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for OGN - Organon - Stock Price & Dividends](https://www.valueray.com/images/chart/OGN.NYSE_seasonality.png)
OGN Stock Overview
Market Cap in USD | 5,395m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 2021-06-02 |
OGN Stock Ratings
Growth 5y | -25.0 |
Fundamental | -4.71 |
Dividend | 56.3 |
Rel. Performance vs Sector | 2.28 |
Analysts | 3.44/5 |
Fair Price Momentum | 25.48 USD |
Fair Price DCF | 52.08 USD |
OGN Dividends
Dividend Yield 12m | 5.05% |
Yield on Cost 5y | 3.89% |
Dividends CAGR 5y | 25.99% |
Payout Consistency | 99.3% |
OGN Growth Ratios
Growth 12m | 6.88% |
Growth Correlation 12m | 30% |
Growth Correlation 3m | 17% |
CAGR 5y | -7.81% |
CAGR/Mean DD 5y | -0.25 |
Sharpe Ratio 12m | 0.04 |
Alpha vs SP500 12m | -10.72 |
Beta vs SP500 5y weekly | 0.79 |
ValueRay RSI | 83.59 |
Volatility GJR Garch 1y | 29.90% |
Price / SMA 50 | 6.02% |
Price / SMA 200 | 30.84% |
Current Volume | 987.6k |
Average Volume 20d | 1444.5k |
External Links for OGN Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of OGN stocks?
As of July 27, 2024, the stock is trading at USD 22.19 with a total of 987,601 shares traded.
Over the past week, the price has changed by +5.77%, over one month by +7.56%, over three months by +21.28% and over the past year by +7.85%.
As of July 27, 2024, the stock is trading at USD 22.19 with a total of 987,601 shares traded.
Over the past week, the price has changed by +5.77%, over one month by +7.56%, over three months by +21.28% and over the past year by +7.85%.
What are the forecast for OGN stock price target?
According to ValueRays Forecast Model, OGN Organon will be worth about 27.5 in July 2025. The stock is currently trading at 22.19. This means that the stock has a potential upside of +24.02%.
According to ValueRays Forecast Model, OGN Organon will be worth about 27.5 in July 2025. The stock is currently trading at 22.19. This means that the stock has a potential upside of +24.02%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 22.5 | 1.40 |
Analysts Target Price | 29.3 | 32.0 |
ValueRay Target Price | 27.5 | 24.0 |